LGL Group (NYSEAMERICAN:LGL) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

LGL Group (NYSEAMERICAN:LGL) released its quarterly earnings results on Friday. The industrial products company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.07), FiscalAI reports. LGL Group had a return on equity of 0.16% and a net margin of 1.66%.The firm had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.80 million.

LGL Group Stock Down 1.6%

LGL Group stock opened at $7.43 on Friday. LGL Group has a 52-week low of $5.45 and a 52-week high of $7.57. The firm has a market cap of $48.59 million, a PE ratio of 743.74 and a beta of 0.32. The company’s 50 day moving average is $6.96 and its two-hundred day moving average is $7.06.

Wall Street Analyst Weigh In

Separately, Zacks Research raised LGL Group to a “hold” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold”.

Institutional Trading of LGL Group

An institutional investor recently raised its stake in LGL Group stock. Osaic Holdings Inc. lifted its stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the period. Osaic Holdings Inc. owned about 0.38% of LGL Group worth $154,000 at the end of the most recent quarter. 30.28% of the stock is currently owned by hedge funds and other institutional investors.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.